TY - JOUR T1 - A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial JO - Blood PY - 2013/11/15 AU - Cook G AU - Williams CD AU - Cairns DA AU - Fletcher M AU - Cavenagh JD AU - Snowden JA AU - Parrish C AU - Ashcroft J AU - Yong KL AU - Cavet J AU - Hunter H et al ED - DO - DOI: 10.1182/blood.v122.21.765.765 PB - American Society of Hematology VL - 122 IS - 21 SP - 765 EP - 765 Y2 - 2025/07/08 ER -